| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vitro |
In mouse L1210 leukemia cells, trichomsalen (200 nM) combined with 365 nm light causes DNA cross-links but not breaks [4]. A synergistic effect of treating HaCaT keratinocytes with trioxsalen and UVA is the induction of NF-kappaB binding activity [5]. In vitro, trichsalen has demonstrated anti-inflammatory properties [5].
|
|---|---|
| ln Vivo |
In rat oral mucosa (OMM), doxsalen induces dose-dependent depletion of ATPase-positive LC using PUVA (UVA dose of 1-8 J/cm2), with a maximum depletion of 80% [3].
|
| References |
|
| Additional Infomation |
Trioxsalen is a 7H-furan[3,2-g]chromen-7-one with methyl groups at positions 2, 5, and 9. Like other psoralen compounds, trioxsalen causes photosensitivity in the skin. It is used orally in combination with UV-A for phototherapy of vitiligo. Upon photoactivation, it forms interstrand crosslinks in DNA, inhibiting DNA synthesis and cell division, and may cause cell damage; after cell damage heals, epidermal melanin deposition may increase. It is both a photosensitizer and a dermatological drug. Trioxsalen (trimethylpsoralen, trioxsalen, or tripsoralen) is a furanocoumarin compound and a psoralen derivative extracted from various plants (primarily psoralen). Like other psoralen compounds, it causes photosensitivity in the skin. It can be administered topically or orally and in combination with UV-A (the least damaging form of ultraviolet radiation) for phototherapy of vitiligo and hand eczema. The photoactivated form creates interstrand crosslinks in DNA, leading to apoptosis. In studies, it can be combined with confocal microscopy dyes for visualization of DNA damage sites. [3] This compound has been used to develop antisense oligonucleotides that can specifically crosslink with mutant mRNA sequences without affecting normal transcripts even if there is only one base pair different.
Trioxalin is a psoralen. Trioxalin has been reported to be found in celery (Apium graveolens), and there is relevant data. A pigment photosensitizer extracted from a variety of plants, primarily Psoralea corylifolia. It can be administered topically or orally and in combination with ultraviolet light for the treatment of vitiligo. Drug Indications Trioxalin is a pigment photosensitizer used in combination with ultraviolet light for the treatment of vitiligo. Mechanism of Action Upon photoactivation, it forms interstrand crosslinks in DNA, leading to programmed cell death. Pharmacodynamics Trioxazone itself has no pharmacological activity, but when exposed to ultraviolet light or sunlight, it is converted into its active metabolites, which can have a beneficial effect on diseased tissues. |
| Exact Mass |
228.078
|
|---|---|
| CAS # |
3902-71-4
|
| PubChem CID |
5585
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
389.0±30.0 °C at 760 mmHg
|
| Melting Point |
229-231ºC(lit.)
|
| Flash Point |
189.1±24.6 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.613
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
374
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C([H])([H])[H])=C([H])C2=C([H])C3C(C([H])([H])[H])=C([H])C(=O)OC=3C(C([H])([H])[H])=C12
|
| InChi Key |
FMHHVULEAZTJMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3
|
| Chemical Name |
2,5,9-trimethylfuro[3,2-g]chromen-7-one
|
| Synonyms |
NSC71047 NSC 71047 NSC-71047
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~6.6 mg/mL (~28.92 mM)
H2O : ~1 mg/mL (~4.38 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03727061 | RECRUITING | Biological: Nivolumab Drug: Porfimer Sodium Procedure: Interstitial Illumination Photodynamic Therapy Other: Quality of Life Assessment |
Locally Advanced Head and Neck Carcinoma Recurrent Head and Neck Carcinoma |
Roswell Park Cancer Institute | 2019-07-10 | Phase 1 |
| NCT03344861 | COMPLETEDWITH RESULTS | Drug: Porfimer Sodium Device: Fiber optic |
Lung Cancer Lung Cancer Metastatic |
Concordia Laboratories Inc | 2017-08-14 | Phase 1 |
| NCT04425746 | COMPLETEDWITH RESULTS | Drug: Afamelanotide Drug: Placebo |
Patients Undergoing Photodynamic Therapy Using Porfimer Sodium |
Clinuvel Pharmaceuticals Limited | 2008-08-05 | Phase 2 |
| NCT02082522 | TERMINATEDWITH RESULTS | Drug: Photodynamic therapy-Photofrin Procedure: Stenting procedure Drug: Chemotherapy regimen |
Hilar Cholangiocarcinoma | Concordia Laboratories Inc | 2014-11-12 | Phase 3 |
| NCT00118222 | COMPLETED | Drug: porfimer sodium Procedure: adjuvant therapy Procedure: conventional surgery |
Brain and Central Nervous System Tumors | Case Comprehensive Cancer Center | 2005-03 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
